talquetamab
Jump to navigation
Jump to search
Indications
- relapsed or refractory multiple myeloma
Dosage
- 0.4 mg weekly or 0.8 mg every other week
Mechanism of action
- bispecific monoclonal antibody against CD3 & GPRC5D
More general terms
References
- ↑ Bassett M Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma. Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients. MedPage Today December 11, 2022 https://www.medpagetoday.com/meetingcoverage/ashhematology/102186
Chari A, Minnema MC, Berdeja JG et al Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022. Dec 10. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36507686 https://www.nejm.org/doi/full/10.1056/NEJMoa2204591 - ↑ Verkleij CPM, Broekmans MEC, van Duin M et al Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2196-2215 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33890981 PMCID: PMC8095149 Free PMC article